Protein Summary
May play a role as a negative regulatory factor in CD4-dependent T-cell activation. The protein encoded by this gene binds to the hydrophobic C-terminal amino acids of CD4 which are involved in repression of T cell activation. The interaction with CD4 is mediated by the noncatalytic alpha/beta hydrolase fold domain of this protein. It is thus proposed that this gene product modulates the stimulatory activity of CD4. Mutations in this gene are associated with autosomal recessive spastic paraplegia 21 (SPG21), also known as mast syndrome. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug 2014]
- ENST00000204566
- ENSP00000204566
- ENSG00000090487
- ENST00000416889
- ENSP00000394846
- ENST00000433215
- ENSP00000404111
- ACP33
- MAST
- ACP33
- GL010
- ABHD21
- BM-019
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
disease perturbation | 1 | ||
transcription factor perturbation | 0.98 | ||
kinase perturbation | 0.97 | ||
virus perturbation | 0.92 | ||
histone modification site profile | 0.84 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 17.53 (req: < 5)
Gene RIFs: 3 (req: <= 3)
Antibodies: 100 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 17.53 (req: >= 5)
Gene RIFs: 3 (req: > 3)
Antibodies: 100 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 2
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0